236 related articles for article (PubMed ID: 19509418)
1. Negative regulation of Stat3 by activating PTPN11 mutants contributes to the pathogenesis of Noonan syndrome and juvenile myelomonocytic leukemia.
Zhang W; Chan RJ; Chen H; Yang Z; He Y; Zhang X; Luo Y; Yin F; Moh A; Miller LC; Payne RM; Zhang ZY; Fu XY; Shou W
J Biol Chem; 2009 Aug; 284(33):22353-22363. PubMed ID: 19509418
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defects.
Solman M; Blokzijl-Franke S; Piques F; Yan C; Yang Q; Strullu M; Kamel SM; Ak P; Bakkers J; Langenau DM; Cavé H; den Hertog J
Elife; 2022 May; 11():. PubMed ID: 35535491
[TBL] [Abstract][Full Text] [Related]
3. Functional evaluation of circulating hematopoietic progenitors in Noonan syndrome.
Timeus F; Crescenzio N; Baldassarre G; Doria A; Vallero S; Foglia L; Pagliano S; Rossi C; Silengo MC; Ramenghi U; Fagioli F; Cordero di Montezemolo L; Ferrero GB
Oncol Rep; 2013 Aug; 30(2):553-9. PubMed ID: 23756559
[TBL] [Abstract][Full Text] [Related]
4. Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment.
Dong L; Yu WM; Zheng H; Loh ML; Bunting ST; Pauly M; Huang G; Zhou M; Broxmeyer HE; Scadden DT; Qu CK
Nature; 2016 Nov; 539(7628):304-308. PubMed ID: 27783593
[TBL] [Abstract][Full Text] [Related]
5. Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.
Xu D; Liu X; Yu WM; Meyerson HJ; Guo C; Gerson SL; Qu CK
J Exp Med; 2011 Sep; 208(10):1977-88. PubMed ID: 21930766
[TBL] [Abstract][Full Text] [Related]
6. Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner.
Zheng H; Yu WM; Waclaw RR; Kontaridis MI; Neel BG; Qu CK
Sci Signal; 2018 Mar; 11(522):. PubMed ID: 29559584
[TBL] [Abstract][Full Text] [Related]
7. SHP2 sails from physiology to pathology.
Tajan M; de Rocca Serra A; Valet P; Edouard T; Yart A
Eur J Med Genet; 2015 Oct; 58(10):509-25. PubMed ID: 26341048
[TBL] [Abstract][Full Text] [Related]
8. Occurrence of acute lymphoblastic leukemia and juvenile myelomonocytic leukemia in a patient with Noonan syndrome carrying the germline PTPN11 mutation p.E139D.
Pauli S; Steinemann D; Dittmann K; Wienands J; Shoukier M; Möschner M; Burfeind P; Manukjan G; Göhring G; Escherich G
Am J Med Genet A; 2012 Mar; 158A(3):652-8. PubMed ID: 22315187
[TBL] [Abstract][Full Text] [Related]
9. Juvenile xanthogranuloma in Noonan syndrome.
Ali MM; Gilliam AE; Ruben BS; Tidyman WE; Rauen KA
Am J Med Genet A; 2021 Oct; 185(10):3048-3052. PubMed ID: 34032360
[TBL] [Abstract][Full Text] [Related]
10. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia.
Lipka DB; Witte T; Toth R; Yang J; Wiesenfarth M; Nöllke P; Fischer A; Brocks D; Gu Z; Park J; Strahm B; Wlodarski M; Yoshimi A; Claus R; Lübbert M; Busch H; Boerries M; Hartmann M; Schönung M; Kilik U; Langstein J; Wierzbinska JA; Pabst C; Garg S; Catalá A; De Moerloose B; Dworzak M; Hasle H; Locatelli F; Masetti R; Schmugge M; Smith O; Stary J; Ussowicz M; van den Heuvel-Eibrink MM; Assenov Y; Schlesner M; Niemeyer C; Flotho C; Plass C
Nat Commun; 2017 Dec; 8(1):2126. PubMed ID: 29259247
[TBL] [Abstract][Full Text] [Related]
11. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG
Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238
[TBL] [Abstract][Full Text] [Related]
12. Increased c-Jun expression and reduced GATA2 expression promote aberrant monocytic differentiation induced by activating PTPN11 mutants.
Yang Z; Kondo T; Voorhorst CS; Nabinger SC; Ndong L; Yin F; Chan EM; Yu M; Würstlin O; Kratz CP; Niemeyer CM; Flotho C; Hashino E; Chan RJ
Mol Cell Biol; 2009 Aug; 29(16):4376-93. PubMed ID: 19528235
[TBL] [Abstract][Full Text] [Related]
13. Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11).
Qiu W; Wang X; Romanov V; Hutchinson A; Lin A; Ruzanov M; Battaile KP; Pai EF; Neel BG; Chirgadze NY
BMC Struct Biol; 2014 Mar; 14():10. PubMed ID: 24628801
[TBL] [Abstract][Full Text] [Related]
14. Co-occurrence of hypertrophic cardiomyopathy and myeloproliferative disorder in a neonate with Noonan syndrome carrying Thr73Ile mutation in PTPN11.
Yagasaki H; Nakane T; Hasebe Y; Watanabe A; Kise H; Toda T; Koizumi K; Hoshiai M; Sugita K
Am J Med Genet A; 2015 Dec; 167A(12):3144-7. PubMed ID: 26286251
[TBL] [Abstract][Full Text] [Related]
15. Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia.
Mulero-Navarro S; Sevilla A; Roman AC; Lee DF; D'Souza SL; Pardo S; Riess I; Su J; Cohen N; Schaniel C; Rodriguez NA; Baccarini A; Brown BD; Cavé H; Caye A; Strullu M; Yalcin S; Park CY; Dhandapany PS; Yongchao G; Edelmann L; Bahieg S; Raynal P; Flex E; Tartaglia M; Moore KA; Lemischka IR; Gelb BD
Cell Rep; 2015 Oct; 13(3):504-515. PubMed ID: 26456833
[TBL] [Abstract][Full Text] [Related]
16. Noonan Syndrome-related Myeloproliferative Disorder Occurring in the Neonatal Period: Case Report and Literature Review.
Hoshino Y; Moriya K; Mitsui-Sekinaka K; Hashimoto Y; Nakayama S; Sajiki D; Muramatsu H; Hagiwara H; Suzuki S; Sekinaka Y; Wakamatsu H; Kawaguchi H; Imai K
J Pediatr Hematol Oncol; 2024 Mar; 46(2):e176-e179. PubMed ID: 38132703
[TBL] [Abstract][Full Text] [Related]
17. Activating PTPN11 mutants promote hematopoietic progenitor cell-cycle progression and survival.
Yang Z; Li Y; Yin F; Chan RJ
Exp Hematol; 2008 Oct; 36(10):1285-96. PubMed ID: 18640765
[TBL] [Abstract][Full Text] [Related]
18. Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation.
Araki T; Chan G; Newbigging S; Morikawa L; Bronson RT; Neel BG
Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4736-41. PubMed ID: 19251646
[TBL] [Abstract][Full Text] [Related]
19. Juvenile myelomonocytic leukaemia and Noonan syndrome.
Strullu M; Caye A; Lachenaud J; Cassinat B; Gazal S; Fenneteau O; Pouvreau N; Pereira S; Baumann C; Contet A; Sirvent N; Méchinaud F; Guellec I; Adjaoud D; Paillard C; Alberti C; Zenker M; Chomienne C; Bertrand Y; Baruchel A; Verloes A; Cavé H
J Med Genet; 2014 Oct; 51(10):689-97. PubMed ID: 25097206
[TBL] [Abstract][Full Text] [Related]
20. Protein tyrosine phosphatase SHP2/PTPN11 mistargeting as a consequence of SH2-domain point mutations associated with Noonan Syndrome and leukemia.
Müller PJ; Rigbolt KT; Paterok D; Piehler J; Vanselow J; Lasonder E; Andersen JS; Schaper F; Sobota RM
J Proteomics; 2013 Jun; 84():132-47. PubMed ID: 23584145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
